

## AMENDMENTS TO THE CLAIMS

1 (Previously Amended). A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human short heterodimer partner-1 (SEQ ID NO: 3), wherein said compound specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding short heterodimer partner-1.

2 (Original). The compound of claim 1 which is an antisense oligonucleotide.

3 (Cancelled).

4 (Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5 (Original). The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6 (Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7 (Original). The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8 (Original). The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9(Original). The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10(Original). The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11(Previously Amended). A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding human short heterodimer partner-1 (SEQ ID NO: 3).

*B*  
12(Original). A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13(Original). The composition of claim 12 further comprising a colloidal dispersion system.

14(Original). The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15(Currently Amended). A method of inhibiting the expression of short heterodimer partner-1 in cells or tissues comprising contacting said cells or tissues in vivo with the compound of claim 1 so that expression of short heterodimer partner-1 is inhibited.

Claims 16-20 (Cancelled).